Zandelisib and B-Cell Lymphomas

被引：0
作者：
O'Brien, Susan [1 ]
Zelenetz, Andrew D. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Qual Informat, New York, NY 10065 USA
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2023年 / 21卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：117 / 119
页数：3
相关论文
共 4 条
  • [1] Zandelisib (ME-401) in Japanese patients with relapsed or refractory indolent non-Hodgkin's lymphoma: an open-label, multicenter, dose-escalation phase 1 study
    Goto, Hideki
    Izutsu, Koji
    Ennishi, Daisuke
    Mishima, Yuko
    Makita, Shinichi
    Kato, Koji
    Hanaya, Miyoko
    Hirano, Satoshi
    Narushima, Kazuya
    Teshima, Takanori
    Nagai, Hirokazu
    Ishizawa, Kenichi
    [J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2022, 116 (06) : 911 - 921
  • [2] Jurczak W, 2021, J CLIN ONCOL, V39
  • [3] Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trial
    Pagel, John M.
    Soumerai, Jacob
    Reddy, Nishitha
    Jagadeesh, Deepa
    Stathis, Anastasios
    Asch, Adam
    Salman, Huda
    Kenkre, Vaishalee P.
    Iasonos, Alexia
    Llorin-Sangalang, Judith
    Li, Joanne
    Zelenetz, Andrew
    [J]. LANCET ONCOLOGY, 2022, 23 (08) : 1021 - 1030
  • [4] PI3K inhibitors in chronic lymphocytic leukemia: where do we go from here?
    Skanland, Sigrid S.
    Brown, Jennifer R.
    [J]. HAEMATOLOGICA, 2023, 108 (01) : 9 - 21
1